Peptide Drug Conjugation Service
The practice of peptide drug conjugation is a novel approach towards the creation of therapeutics targeting rare diseases and it is one of the most promising forms of drug development at the moment. In our company, one step services for PDC development are available. These services range from the design, optimization to preclinical studies and are focused on the phrase rare disease peptide therapy.
Introduction to Peptide Drug Conjugation
After Antibody drug conjugate (ADC) PDC or peptide drug conjugation emerged, and so did PDC’s capacity to integrate multifaceted steric effectors. PDC's size allows for a lower molecular weight, severe autoimmune reactions are less likely, and they are easy to make. PDC is made up of targeting peptides, lethal chunks, and intermediates that make it possible for the delivery of chemotherapy drugs.
Fig.1 PDC delivery route in vivo (Fu, Chen, et al. 2023)
PDC for Rare Diseases
Along with various peptides also serves as targeting moieties for drug delivery. Peptides have been used in aiding the therapeutic of endocrine and certain rare cancers. Their distinct features, better cell permeability and enhanced selectivity PDC is the next ADC. Developing countries such as Tunisia, Brazil and Lebanon have already purchased several types of these drugs.
| Drug Name | Target | Types of Rare Diseases Targeted |
|---|---|---|
| Lutathera | Somatostatin Receptor 2 (SSTR2) | Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) |
| Paclitaxel Trevatide | Low-Density Lipoprotein Receptor (LDLR) | Glioblastoma Multiforme (GBM) |
Our Services
PDC offers a new paradigm in rare disease therapeutics by combining the benefits of peptide-based drugs. Unlike traditional anticancer therapies, PDC utilizes smaller molecular compositions, enhancing biochemical stability, cell membrane penetration, and overall efficacy. Our company offers customized coupling services for peptide carriers, linkers, and payload drugs.
- Peptide Carrier
We offer the common peptide carrier, including cell-penetrating peptides and cell-targeting peptides. - Linkers
Similarly, when it comes to rare diseases, the choice of linker for peptide conjugation is also target-dependent. Factors such as the drug molecule used, the site of conjugation, the number of attachment sites available, and the desired cleavability and polarity of the linker all influence the selection process. We offer a variety of linkers for peptide conjugation, including cleavage linkers and non-cleavage linkers. - Cleavage linkers: Hydrazine (pH-sensitive), Glycine-Phenylalanine-Leucine-Glycine (enzyme-sensitive), Disulfide bond (reduction-sensitive).
- Non-cleavage linkers: Carbon chains, Amido bonds, and Ether bonds.
- Payload Drugs
Any drugs you are interested in include but are not limited to: Doxorubicin (DOX), Paclitaxel (PTX), and Camptothecin (CPT).
Project Workflow
Through ongoing research and development, peptide conjugation continues to pave the way for the future of personalized therapies for rare diseases. If you are interested in our services, please feel free to contact us for more details and quotation information of related services.
Reference
- Fu, Chen, et al. "Peptide–drug conjugates (PDCs): a novel trend of research and development on targeted therapy, hype or hope?." Acta Pharmaceutica Sinica B 13.2 (2023): 498-516.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.